Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States.
abdominal pain
constipation
diarrhea
functional GI diseases
irritable bowel syndrome (IBS)
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
revised:
02
07
2024
received:
20
02
2024
accepted:
18
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits, with patient-perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS-C) and diarrhea (IBS-D). This study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS-C or IBS-D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported. Nine hundred and ten participants with IBS-C and 669 with IBS-D were matched to controls. The most reported symptoms were abdominal discomfort for IBS-C and abdominal pain and abdominal discomfort for IBS-D. Among the IBS-C and IBS-D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over-the-counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over-the-counter medication(s) reported better symptom control than respondents only taking over-the-counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls. This study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over-the-counter medications.
Sections du résumé
BACKGROUND
BACKGROUND
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits, with patient-perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS-C) and diarrhea (IBS-D).
METHODS
METHODS
This study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS-C or IBS-D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported.
KEY RESULTS
RESULTS
Nine hundred and ten participants with IBS-C and 669 with IBS-D were matched to controls. The most reported symptoms were abdominal discomfort for IBS-C and abdominal pain and abdominal discomfort for IBS-D. Among the IBS-C and IBS-D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over-the-counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over-the-counter medication(s) reported better symptom control than respondents only taking over-the-counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls.
CONCLUSIONS AND INFERENCES
CONCLUSIONS
This study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over-the-counter medications.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14903Subventions
Organisme : Ironwood Pharmaceuticals, Inc.
Organisme : AbbVie Inc.
Informations de copyright
© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844‐856.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta‐analysis. Clin Gastroenterol Hepatol. 2012;10(7):712‐721.e4.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908‐917.
Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262‐1273.e3.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99‐114.e3.
Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol. 2012;107(2):286‐295.
Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393‐1407.e5.
Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023‐1034.
Herrick LM, Spalding WM, Saito YA, Moriarty J, Schleck C. A case‐control comparison of direct healthcare‐provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community‐based cohort. J Med Econ. 2017;20(3):273‐279.
Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a US commercially insured population. J Manag Care Spec Pharm. 2017;23(4):453‐460.
Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health‐related quality of life. Gastroenterology. 2000;119(3):654‐660.
Buono JL, Carson RT, Flores NM. Health‐related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.
Zamani M, Alizadeh‐Tabari S, Zamani V. Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132‐143.
Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021;131:709‐715.
Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018;93(12):1858‐1872.
Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17‐44.
Corsetti M, Brown S, Chiarioni G, et al. Chronic constipation in adults: contemporary perspectives and clinical challenges. 2: conservative, behavioural, medical and surgical treatment. Neurogastroenterol Motil. 2021;33(7):e14070.
Liu JJ, Brenner DM. Review article: current and future treatment approaches for IBS with constipation. Aliment Pharmacol Ther. 2021;54(Suppl 1):S53‐S62.
Pimentel M. Evidence‐based management of irritable bowel syndrome with diarrhea. Am J Manag Care. 2018;24(3 Suppl):S35‐S46.
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence‐based medicine. World J Gastroenterol. 2014;20(22):6759‐6773.
Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2021;12(4):303‐315.
Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GI Motility Working Group, Lembo A. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey. Gastroenterology. 2020;158(3):786‐788.e1.
Quigley EMM, Horn J, Kissous‐Hunt M, Crozier RA, Harris LA. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS‐C) study: results of an online questionnaire. Adv Ther. 2018;35(7):967‐980.
Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient‐reported data: the chronic constipation and IBS‐C treatment and outcomes real‐world research platform (CONTOR). J Med Econ. 2020;23(10):1072‐1083.
Sonu I, Triadafilopoulos G, Gardner JD. Persistent constipation and abdominal adverse events with newer treatments for constipation. BMJ Open Gastroenterol. 2016;3(1):e000094.
Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17(8):577‐586.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373‐383.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD‐7. Arch Intern Med. 2006;166(10):1092‐1097.
Kroenke K, Spitzer RL, Williams JB. The PHQ‐9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606‐613.
Iqbal SU, Rogers W, Selim A, et al. The Veterans RAND 12 Item Health Survey (VR‐12): what it is and how it is used. 2007 Accessed November 2022. https://www.bu.edu/sph/files/2015/01/veterans_rand_12_item_health_survey_vr‐12_2007.pdf
Selim AJ, Rogers W, Qian SX, Brazier J, Kazis LE. A preference‐based measure of health: the VR‐6D derived from the veterans RAND 12‐item health survey. Qual Life Res. 2011;20(8):1337‐1347.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353‐365.
Ballou S, McMahon C, Lee H‐N, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471‐2478.e3.
Törnblom H, Goosey R, Wiseman G, Baker S, Emmanuel A. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: results from patient and healthcare professional surveys. United European Gastroenterol J. 2018;6(9):1417‐1427.